Dr. Anıl Yıldız

Comparison of First-Line Pembrolizumab Monotherapy Versus Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Multicenter Real-World Study from Turkey

Medicina, 2026

DOI 10.3390/medicina62112136 Frei zugänglicher VolltextQuelle: OpenAlex

Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15062217 PMID 41899145 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Association of Post-Neoadjuvant Chemotherapy MRI and 18F-FDG PET/CT Findings with Tumor Response and Prognosis in Breast Cancer

Diagnostics, 2026

DOI 10.3390/diagnostics16050713 PMID 41827989 Frei zugänglicher VolltextQuelle: OpenAlex

Comparison of clinicopathological features and prognoses of de-novo metastatic male and female bladder cancer patients.

Journal of Clinical Oncology, 2026

DOI 10.1200/jco.2026.44.7_suppl.867 Quelle: OpenAlex

Clinicopathologic Features of NRG1 Fusion‐Positive Non‐Small Cell Lung Cancer

Genes, Chromosomes and Cancer, 2026

DOI 10.1002/gcc.70170 PMID 42706502 Frei zugänglicher VolltextQuelle: ORCID

Drug-related problems, adherence and quality of life in outpatients receiving endocrine treatment for hormone receptor-positive breast cancer: A prospective study

Journal of Oncology Pharmacy Practice, 2026

DOI 10.1177/10781552261494092 PMID 42847533 Frei zugänglicher VolltextQuelle: ORCID

Prognostic Value of the Lung Immune Prognostic Index in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab: A Real-World Analysis Beyond PD-L1 Expression

Diagnostics, 2026

DOI 10.3390/diagnostics16182890 PMID 42793675 Frei zugänglicher VolltextQuelle: ORCID

Impact of HER2-low status on survival outcomes in patients with metastatic breast cancer treated with cdk4/6 inhibitors: A single-center experience

Medical Journal of Western Black Sea, 2026

DOI 10.29058/mjwbs.1844079 Frei zugänglicher VolltextQuelle: ORCID

Prognostic Value of the Lung Immune Prognostic Index in Advanced Non–Small Cell Lung Cancer Receiving Nivolumab: A Real-World Analysis Beyond PD-L1 Expression

2026

DOI 10.20944/preprints202605.1554.v1 Frei zugänglicher VolltextQuelle: ORCID

Prognostic Impact of ABO/Rh Blood Group–Systemic Inflammation Indices Interactions in Small-Cell Lung Cancer

Biomedicines, 2026

DOI 10.3390/biomedicines14051051 PMID 42193377 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Clinicopathologic Determinants of Overall Survival in Adrenocortical Carcinoma: A SEER-Based Population Study

Cancers, 2026

DOI 10.3390/cancers18071103 PMID 41976326 Frei zugänglicher VolltextQuelle: ORCID

Post-Chemotherapy Changes and Agreement of CT-Derived Body Composition at L3 and T12 in Older Patients with Metastatic Colorectal Cancer: Associations with Nutritional Indices and Outcomes

Nutrients, 2026

DOI 10.3390/nu18071090 PMID 41978140 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Prognostic Role of Endocan and Platelet-Derived Growth Factor Isoforms in Metastatic Colorectal Cancer

International Journal of Molecular Sciences, 2026

DOI 10.3390/ijms27062600 PMID 41898463 Frei zugänglicher VolltextQuelle: ORCID

Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer

The Oncologist, 2025

DOI 10.1093/oncolo/oyaf054 PMID 40271640 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Evaluation of Changes in Clinicopathological Features and Prognosis in Patients with Thyroid Cancer

Journal of Clinical Medicine, 2025

DOI 10.3390/jcm14051482 PMID 40094945 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression

Medicina, 2024

DOI 10.3390/medicina60122069 PMID 39768949 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer

Medicina, 2024

DOI 10.3390/medicina60060951 PMID 38929568 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients

Indian Journal of Surgical Oncology, 2024

DOI 10.1007/s13193-024-01936-8 PMID 39239446 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients

TURKISH JOURNAL OF MEDICAL SCIENCES, 2024

DOI 10.55730/1300-0144.5784 PMID 38812646 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Rechallenge of Trastuzumab-based Therapy in HER2-Positive Breast Cancer Patients who Progressed Under TDM-1

Indian Journal of Surgical Oncology, 2024

DOI 10.1007/s13193-024-01935-9 PMID 39239424 Frei zugänglicher VolltextQuelle: OpenAlex

Efficacy of inthratecal therapy in breast cancer patients with Leptomeningeal Metastasis

Eastern Journal Of Medicine, 2024

DOI 10.5505/ejm.2024.42890 Frei zugänglicher VolltextQuelle: OpenAlex

Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Journal of Chemotherapy, 2024

DOI 10.1080/1120009x.2024.2403051 PMID 39257075 2 Zitationen (Europe PMC) Quelle: OpenAlex

Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study

Medicine, 2024

DOI 10.1097/md.0000000000037213 PMID 38394499 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Bevacizumab-related intestinal perforation: A single center experience

European Journal of Surgical Oncology, 2024

DOI 10.1016/j.ejso.2023.107337 1 Zitation (OpenAlex) Quelle: OpenAlex

Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study

Medicine, 2022

DOI 10.1097/md.0000000000031726 PMID 36397338 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience

Clinical Cancer Investigation Journal, 2022

DOI 10.51847/87n2fddtb1 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib

Clinical Cancer Investigation Journal, 2022

DOI 10.51847/rvqewyffbi 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Kan Plazmasında Satellit-2 Tekrar Elementi DNA Dizilerinin Karakterizasyonu

İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi, 2022

DOI 10.38079/igusabder.1105142 Frei zugänglicher VolltextQuelle: ORCID

Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: single center experience from Turkey

Anti-Cancer Drugs, 2022

DOI 10.1097/cad.0000000000001389 PMID 36206103 11 Zitationen (Europe PMC) Quelle: ORCID